CJC-1295 and ipamorelin together: legal status, evidence and risks

Status at a glance

Why they are combined

The pairing rests on mechanism. CJC-1295 is a GHRH analogue; ipamorelin is a growth hormone secretagogue, a separate class that WADA groups with ghrelin mimetics. The marketing argument is that hitting two signals at once releases more growth hormone than either alone. That is a hypothesis about a hormone level, not a demonstrated health outcome.

Human evidence

We did not find a controlled trial of CJC-1295 and ipamorelin given together, and we have not re-read the literature for this update, so we cite no study. For the parts: FDA says clinical data on CJC-1295 are limited, and the human ipamorelin data FDA highlights is a report of serious adverse events, including death, with intravenous use for gastric motility (FDA).

Animal and laboratory evidence

Support for each component comes largely from physiology and animal studies of the growth-hormone axis. Combining two unproven agents does not create proof.

Risks

A combination carries the risks of both parts. FDA has reported increased heart rate and systemic vasodilatory reactions with CJC-1295, and it keeps ipamorelin in 503B Category 2 for safety reasons. Pre-mixed vials from research sellers add uncertainty about how much of each peptide is present.

Legal sourcing: who can supply it

With neither component in a 503A category, a pharmacy has no established federal basis to compound the pair as of October 15, 2026. A clinic offering it should tell you, in writing, which pharmacy compounds it and on what legal basis. See CJC-1295, ipamorelin and the legality guide.

The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.

October 2026: what changed

• April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
• July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
• October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.

For this combination: both components left 503A Category 2 in April, neither was on the July PCAC agenda, and FDA’s August letters targeted ipamorelin blends. Until an interim policy is published and names them, nothing has changed.